Bicalutamide and Alcohol: Interaction Risks and Clinical Advice
Interaction
Alcohol does not have a direct pharmacokinetic interaction with bicalutamide (a non-steroidal antiandrogen), but both are hepatically metabolized and can independently cause liver injury.
Risks of Combined Use
- Additive hepatotoxicity: Increased risk of elevated transaminases, hepatitis, or liver failure.
- Worsening of side effects: Fatigue, hot flashes, GI upset may be exacerbated.
- Compliance: Alcohol may impair adherence to daily dosing.
Clinical Recommendation
- Avoid or strictly limit alcohol during bicalutamide therapy.
- Monitor LFTs (ALT, AST, bilirubin) at baseline, periodically, and with symptoms.
- Report jaundice, dark urine, RUQ pain, unexplained fatigue immediately.
Context
Bicalutamide is used for prostate cancer (often with LHRH agonist) or as monotherapy. Liver toxicity is rare but serious; alcohol unnecessarily increases risk.
Drug Addiction - Related Articles
- Cocaine Addiction Recovery: Understanding and Treatment
- Recovering from Alcohol Abuse: Understanding & Resources
- Understanding and Managing Heroin Withdrawal Symptoms
- Understanding Physiological Drug Addiction: Causes & Impact
- Understanding the Physical Health Risks of Drug Misuse
- Understanding Drug Withdrawal in Newborns: Signs, Symptoms & Care
- Motivational Interviewing: A Comprehensive Guide for Effective Behavior Change
